Early Development Asset Lead

Biopharma Careers; Greater London; Hybrid; GBP 120,000 - 150,000; Full time

Job summary

Ipsen Biopharm Ltd in the United Kingdom is seeking an Early Development Asset Lead (EDAL) to drive scientific and program leadership for one or more early-stage assets. You will lead the Early Development Asset Team (EDT) spanning clinical, regulatory, CMC and translational activities, ensuring rigorous strategy and accountable portfolio decisions.

The EDAL will align with Therapeutic Area strategy, championing assigned programs, articulating goals and scientific rationale, and representing the

Responsibilities

• Leads one or more Early Development Asset Teams.
• Owns integrated program strategy across preclinical, translational, clinical, diagnostic and regulatory activities.
• Develops integrated asset strategy including target product profile and portfolio decisions.

Job description

## About this opportunity**Title:**Early Development Asset Lead**Company:**Ipsen Biopharm Ltd**About Ipsen:**Ipsen is a mid-sized global biopharmaceutical company with a focus on transformative medicines in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Supported by nearly 100 years of development experience, with global hubs in the U.S., France and the U.K, we tackle areas of high unmet medical need through research and innovation.Our passionate teams in more than 40 countries are focused on what matters and endeavor every day to bring medicines to patients in 88 countries. We build a workplace that champions human-centric leadership and fosters a culture of collaboration, excellence and impact. At Ipsen, every individual is empowered to be their true selves, grow and thrive alongside the company’s success. Join us on our journey towards sustainable growth, creating real impact on patients and society!For more information, visit us at **https://www.ipsen.com/** and follow our latest news on **LinkedIn** and **Instagram** .**Job Description:**Early Development Asset LeadDivision / Function: Early Development and InnovationSummary / Purpose of the PositionThe Early Development Asset Lead (EDAL) is a scientific and program leadership role within Ipsen's Early Development and Innovation organization, accountable for integrated development strategy and execution for one or more early-stage therapeutic assets from drug candidate nomination through first-in-human clinical trials.The EDAL leads the Early Development Asset Team (EDT), a cross-functional matrix team spanning clinical, regulatory, CMC, translational, clinical pharmacology, nonclinical safety, and biomarkers, ensuring that each program advances with scientific rigor, strategic clarity, and accountability to portfolio decisions. The EDAL maintains alignment with Therapeutic Area strategy to ensure EDT plans support agreed portfolio priorities, and serves as the scientific champion for assigned programs, articulating project goals, scientific rationale, and clinical line of sight internally and externally. Depending on pipeline needs, the EDAL may represent Early Development in due diligence as the ED lead within a multidisciplinary global team.Main Responsibilities / Job ExpectationsProgram Leadership and Strategy• Leads one or more Early Development Asset Teams.• Owns integrated program strategy across preclinical, translational, clinical, diagnostic, and regulatory activities.• Develops and maintains integrated asset strategy, including target product profile, indication strategy, key development options, competitive context, and evidence required for decision-making.